<DOC>
	<DOCNO>NCT02265627</DOCNO>
	<brief_summary>To investigate pharmacokinetics single dose BIIL 284 BS patient hepatic impairment comparison healthy subject</brief_summary>
	<brief_title>Pharmacokinetics , Safety Tolerability BIIL 284 BS Patients With Hepatic Impairment Comparison Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<criteria>Healthy Subjects Written inform consent sign date prior participation study ( include medication washout ) Male female 2470 year age All subject within ( + 20 % ) ideal body weight ( BrocaIndex ) Healthy subject must able comparably match hepatic impaired patient accord age ( + 5 year ) , weight ( + 30 lb ) , gender , smoke status Volunteers evidence clinically relevant concomitant disease base upon follow : detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , complete blood count ( CBC ) differential platelet , prothrombin time ( PT ) , blood chemistry , hematology urinalysis Female subject need nonchildbearing potential ( postmenopausal ) , tubal ligation total hysterectomy ) provide negative pregnancy test screen visit subject male Tested negative screen visit follow drug screen panel ( barbiturate , benzodiazepine , amphetamine , opiate , cocaine , cannabinoids ) Patients hepatic impairment Written inform consent sign date prior participation study ( include medication washout ) Male female 2470 year age All subject within ( + 20 % ) ideal body weight ( BrocaIndex ) Proven history cirrhosis confirm liver/spleen scan biopsy ( within one year ) Hepatic impairment : A ChildPugh classification Class A , B Volunteers evidence clinically relevant concomitant disease ( hepatic impairment ) base upon follow : detailed medical surgical history , complete physical examination include vital sign , 12lead ECG , CBC differential platelet , prothrombin time ( PT ) , blood chemistry , hematology urinalysis Tested negative screen visit follow drug screen panel ( barbiturate , benzodiazepine , amphetamine , opiate , cocaine , cannabinoids ) . Unless know drug use medicinal reason . For reason sponsor investigator notify Female patient nonchildbearing potential ( postmenopausal ) , tubal ligation total hysterectomy ) provide negative pregnancy test screen visit Healthy subject Tested positive Hepatitis B surface antigen , Hepatitis C antibody HIV antibody Have significant acute chronic disease , could interfere objective study Small difficult locate arm hand vein would impair clinician 's ability draw multiple blood sample place venous catheter Likely need concomitant medication study period , could interfere objective study Had give blood donation month precede study drug administration Alcohol consumption &gt; 2 drink daily ( one drink define : 12 ounce beer , 4 ounce wine 1.5 ounce spirit ) Coffee tea consumption &gt; 3 cup per day xanthine contain drink &gt; 0.5 liter/day History clinically significant hematological , respiratory , cardiovascular , renal central nervous system ( CNS ) disease medical condition capable alter metabolism elimination drug , constitute risk factor take study drug History drug addiction alcoholism Any medical psychological condition could relapse immediately study Use drug nutrient could induce inhibit hepatic microsomal enzyme within one month start study longer base elimination halflife drug Use experimental new drug one month prior study drug administration Consumed medicine whatsoever ( include counter ( OTC ) drug ) within two week schedule administration study drug Patients Hepatic Impairment Positive serology HIV Have significant acute chronic disease ( except hepatic disease ) , unstable could interfere objective study Small difficult locate arm hand vein would impair clinician 's ability draw multiple blood sample place venous catheter Have hepatocellular carcinoma , extrahepatic biliary obstruction , surgical portalsystemic shunting , acute hepatitis origin Digestive bleeding within one month inclusion Likely need concomitant medication study period , could interfere objective study Had give blood donation month precede study entry Coffee tea consumption &gt; 3 cup per day xanthine contain drink &gt; 0.5 liter/day History clinically significant hematological , respiratory , cardiovascular , renal CNS disease medical condition ( except hepatic impairment ) capable alter metabolism elimination drug , constitute risk factor take study drug Any medical psychological condition could relapse immediately study Use drug nutrient could induce inhibit hepatic microsomal enzyme within one month start study longer base elimination halflife drug Use experimental new drug within previous month</criteria>
	<gender>All</gender>
	<minimum_age>24 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>